Expression of the ErbB family of receptors in ovarian cancer

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 3, 1998, Pages 161-165

  Scoccia, Bert ^a   Lee, Young Mi ^a   Niederberger, Craig ^a   Ilekis, John V ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ErbB; Growth factor receptors; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYSTADENOCARCINOMA; DENSITOMETRY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; OVARY CANCER; PRIORITY JOURNAL; TISSUE LEVEL;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0344813712     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(98)00006-9     Document Type: Article

References (37)

1. Grunt TW, Huber H. The family of c-erbB genes from basic research to clinical oncology . Oncologie. 17:1994;346-357.
2. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 4:1992;1-24.
3. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 12:1993;255-274.
4. Blechman JM, Lev S, Barg J, et al. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell. 80:1995;103-113.
5. Peles E, Yarden Y. Neu and its ligands from an oncogene to neural factors . Bioessays. 15:1993;815-824.
6. Wen D, Suggs SV, Karunagaran D, et al. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol. 14:1994;1909-1919.
7. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 16:1996;5276-5287.
8. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
9. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
10. Fantl WJ, Johnson DE, Williams LT. Signaling by receptor tyrosine kinases. Annu Rev Biochem. 62:1993;453-481.
11. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 10:1994;251-257.
12. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family evidence for overexpression in a subset of human mammary tumors . Proc Natl Acad Sci USA. 86:1989;9193-9197.
13. Batzer AG, Rotin D, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Sch on the epidermal growth factor receptor. Mol Cell Biol. 14:1994;5192-5201.
14. Seger R, Krebs EG. The MAP kinase signaling cascade. FASEB J. 9:1995;726-735.
15. Earp HS, Dawson TL, Li Xiong, Yu H. Heterodimerization and functional interaction between EGF receptor family members A new signaling paradigm with implications for breast cancer research . Breast Cancer Res Treat. 35:1995;115-132.
16. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:1996;2452-2467.
17. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cel Biol. 14:1991;3550-3558.
18. Gullick WJ. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer. 4:(Suppl 5):1990;55-61.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer Correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
20. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence and of death from breast cancer. Lancet. i:1987;1398-1402.
21. Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 164:1991;669-674.
22. Scambia G, Panici PB, Battaglia F, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 10:1992;529-535.
23. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER/2-neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
24. Schroeder W, Biesterfeld S, Zilllessen S, Rath W. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res. 17:1997;2799-2802.
25. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer immunohistochemical findings and prognostic value . J Obstet Gynaecol. 21:1995;167-178.
26. Scrov SF, Scully RE. Histological typing of ovarian tumors. International Histilogical Classification of Tumors, No. 9. Geneva: World Health Organization, 1973.
27. International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis . J Int Fed Gynecol. 3:1965;204.
28. Ilekis JV, Gariti J, Niederberger C, Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol. 65:1997;36-41.
29. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 66:1997;250-254.
30. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 50:1990;3947-3951.
31. Karlan BY, Jones J, Slamon DJ, Lagasse LD. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol. 53:1994;70-77.
32. Yoshihiro J, Merlino GT, Pastan I. A novel effect of EGF on mRNA stability. Nucl Acids Res. 16:1988;4957-4966.
33. Ewing TM, Murphy LJ, Ng M-L, et al. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer. 44:1989;744-752.
34. Johnson AC. Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristatge 13-acetate is mediated by activator protein 2. J Biol Chem. 271:1996;3033-3038.
35. Kokai Y, Myers JN, Wadat T, et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 58:1989;287.
36. Simpson BJB, Weatherill J, Miller EP, Lessells AM, Langdon SP, Miller WR. C-erbB-3 protein expression in ovarian tumours. Br J Cancer. 71:1995;758-762.
37. Simpson JB, Phillips HA, Lessells AM, Landgon SP, Miller WR. c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer. 64:1995;202-206.